Cell and Gene Manufacturing and Logistics

  1. Enhanced Flow Kit Performance With Leak And PUPSIT Testing 1/13/2026

    Sterile drug filtration demands rigorous integrity testing to prevent contamination. Learn how PUPSIT and in situ leak testing strengthen compliance with EU GMP Annex 1 and ensure reliable manufacturing.

  2. Automated PUPSIT For Drug Product Applications 1/13/2026

    Automated filtration systems streamline PUPSIT, leak testing, and integrity checks to ensure sterile drug product processing. Learn how these methods improve contamination control and compliance.

  3. Single-Use Standards Are Maturing, But The Process Remains King 1/13/2026

    The food industry inspired single-use in biopharma, but the regulatory landscape is far more complex. If you're worried about compliance, this discussion can help.

  4. Wetting Recommendations For Successful Filter Integrity Testing 1/12/2026

    Discover best practices for hydrophobic and hydrophilic filters, troubleshoot failures, and optimize wetting in stainless steel and single-use systems to ensure process reliability and product quality.

  5. Optimized Product Recovery Using The Drug Product Filtration System 1/12/2026

    Explore strategies to maximize drug product recovery during sterile filtration, minimize hold-up volume, and reduce dilution after PUPSIT to ensure higher yield, improved efficiency, and less waste.

  6. How CDMOs Are Evolving To Serve A Diverse And Emerging CGT Market 1/12/2026

    This segment of Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing featuring expert panelists Steve Awad, Principal Director, Supply Chain & Industry X — Life Sciences, Accenture, and Michael Blackton, MBA, VP, Manufacturing and Supply at Ocugen, explored how the CDMO landscape is adapting to support the growing diversity of CGT modalities, particularly for small and mid-sized developers that often lack in-house capabilities.

  7. Digital Strategies Driving Efficiency And Throughput In CGT Manufacturing 1/12/2026

    This segment of Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing featuring expert panelists Steve Awad, Principal Director, Supply Chain & Industry X — Life Sciences, Accenture, and Michael Blackton, MBA, VP, Manufacturing and Supply at Ocugen focused on how digital and operational innovation is reshaping efficiency, cost control, and capacity planning in CGT manufacturing.

  8. Capacity, Risk, And The Role Of Digital Innovation 1/12/2026

    This portion of Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing featuring expert panelists Steve Awad, Principal Director, Supply Chain & Industry X — Life Sciences, Accenture, and Michael Blackton, MBA, VP, Manufacturing and Supply at Ocugen focused on how developers can assess whether a CDMO is truly equipped to support multimodal programs without introducing capacity bottlenecks, quality drift, or compliance risk. Our experts emphasized that credible CDMOs demonstrate both process maturity through documented, consistently followed planning practices and digital maturity with robust capacity models and simulation tools rather than ad hoc spreadsheets.

  9. Scaling Quality And Managing Cost Pressures Across CGTs 1/12/2026

    During Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing featuring expert panelists Steve Awad, Principal Director, Supply Chain & Industry X — Life Sciences, Accenture, and Michael Blackton, MBA, VP, Manufacturing and Supply at Ocugen examined how CGT developers can scale quality organizations without creating unsustainable overhead, while also addressing the distinct cost pressures of cell versus gene therapy manufacturing.

  10. Workforce Readiness And A Final Checklist For Multi-Modal CDMO Selection 1/12/2026

    The closing segment of Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing featuring expert panelists Steve Awad, Principal Director, Supply Chain & Industry X — Life Sciences, Accenture, and Michael Blackton, MBA, VP, Manufacturing and Supply at Ocugen emphasized that true multi-modal readiness depends as much on people and governance as on facilities and technology. Our experts stressed the importance of a deeply trained, modality-specific workforce, shaped by practical factors such as geographic access to skilled aseptic operators, alongside robust training strategies to build talent where gaps exist.